Skip to content
Logo text: ISPOR Improving healthcare decisions

Health Technology Assessment Central

The HTA Resource Center for Informing Healthcare Decisions

  • Home
  • What Is HTA?
  • HTA News and Events
  • Resource Library
  • Governance
  • Policy Interchange
  • Training and Development
« Back to ISPOR.org

News

Turning European HTA Reform Into Level for Controlling Drug Developers

June 7, 2018

http://www.appliedclinicaltrialsonline.com/turning-european-hta-reform-level-controlling-drug-developers

Posted in: Uncategorized

Post navigation

← The Commission’s Proposal on Health Technology Assessment – Will the EU Member States Accept its Mandatory Provisions?
English translation of IQWiG’s updated General Methods now available →

News

The new definition of HTA: A milestone in international collaboration
Impact of a Global Pandemic on Health Technology Assessment
NEW HTAi – ISPOR Joint Deliberative Processes for HTA Task Force
Strategic collaboration announced by NICE and Health Technology Wales
NICE and LSE announce new Executive MSc in Evaluation of Health Care Interventions and Outcomes degree program, starting in April 2020
Why HTA and Pooled Purchasing Must Be at the Heart of Global Health Transitions
Health Technology Assessment Around the World: Broadening the Understanding of Cross-Country Differences
Ghana’s HTA agenda and UHC, what difference could HTA make?
AMCP releases the AMCP Format for Formulary Submissions, version 4.1
The ‘Top 10’ Challenges for Health Technology Assessment: INAHTA Viewpoint

Twitter

Tweets about #HTA

#HTA

idsihealthiDSI@idsihealth·
3h

#Ghana just launched its first Strategy for Health Technology Assessment, sending a clear message of ambitious commitment to evidence informed #prioritysetting.

With use of #HTA still very limited in SSA, the strategy represents a regional achievement.

https://bit.ly/3fxGxUS

Reply on Twitter 1422943254841004039Retweet on Twitter 14229432548410040392Like on Twitter 14229432548410040394Twitter 1422943254841004039
pulsuumPulsuum@pulsuum·
3h

La #hipertensión no se cura. Se controla.
@pulsuum #HTA #diabetes #salud #cardio
https://cutt.ly/YyLsEAV

Reply on Twitter 1422932852639944705Retweet on Twitter 1422932852639944705Like on Twitter 1422932852639944705Twitter 1422932852639944705
JanssenEMEAJanssen EMEA@JanssenEMEA·
4h

Martin Price, our VP of Health Economics, Market Access and Reimbursement, shares key takeaways from a recent @HTAiOrg symposium about the need to evolve #HTA frameworks to keep pace with novel #cancer therapies and accelerate access for patients. https://bit.ly/3lv9IM4

Reply on Twitter 1422928724975104004Retweet on Twitter 1422928724975104004Like on Twitter 1422928724975104004Twitter 1422928724975104004
Load More...
Privacy Policy | Disclaimer
Copyright © 2021 ISPOR – The Professional Society for Health Economics and Outcomes Research